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Background: Qingfei Xiaoyan Wan (QFXY), a traditional Chinese formula, is widely used for relieving cough, asthma,
upper respiratory tract infection, bronchitis, pneumonia, and etc. in clinic. Comparing with other anti-asthma drugs,
it is characterised with moderate and persistent efficacy as well as few side effects, however, the underlying action
mechanism still remains elusive. This study aimed to identify QFXY multi-target network regulation as an asthma
controller.
Methods: This study established asthma model induced by histamine phosphate and acetylcholine chloride
(His&Ach) in guinea pigs, which then were administered orally with QFXY. Hematoxylin-Eosin staining sections were
applied for evaluating QFXY effect. In both Model and QFXY groups, customized microarrays and 2D
electrophoresis were adopted to detect differentially expressed genes (diff genes) and proteins (diff proteins)
respectively, and some diff proteins were identified with MALDI-TOF/MS. The checked diff genes and proteins
underwent Cluster, GO and KEGG analysis. Based on GAD and HPRD databases, QFXY-asthma target regulation
network was constructed.
Results: His&Ach-induced asthma model of guinea pigs was established. HE sections presented anti-inflammation
and anti-remodelling effects of QFXY. Comparing with the Model group, 55 diff genes and 6 diff proteins were
identified in QFXY group. Validation by qPCR and Western blot showed the microarray and 2D data reliable.
Furthermore, QFXY-asthma target regulation network was achieved.
Conclusions: A primarily combined genomic and proteomic screening of QFXY targets displayed a series of
candidate genes and proteins, which indicated that the effect of QFXY relied on the combined mechanism,
anti-inflammation and anti-remodelling, as well as influencing signal transduction in vivo.
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Multi-target networkBackground
Asthma, as defined in 2008 by the Global Initiative for
Asthma (GINA), is an inflammatory disorder of the air-
ways in which many cells and cellular elements play
roles [1]. Bronchial hyperactivity associates with inflam-
mation, that together with an external or environmental
insult, on a vulnerable bronchial epithelial structures,
generates tissue remodelling and respiratory functional
impairment [2]. Asthma is not a curable disease at the
present time [3,4]. However, with proper treatments, the
risk of mortality for asthmatic individuals could be* Correspondence: wuhongmedu@126.com
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reproduction in any medium, provided the orcomparable to that of the general population. Presently,
the treatment of asthma includes a dual focus: the short-
term treatment of acute symptoms with bronchodilators,
and together with the prevention or eventual reversal of
chronic inflammation using anti-inflammatory drugs [5].
Medications to treat asthma can be classified as con-
trollers or relievers. Controllers are medications taken
daily on a longterm basis to keep asthma under clinical
control chiefly through their anti-inflammatory effects.
Relievers are medications used on an as-needed basis,
which act quickly to reverse bronchoconstriction and re-
lieve its symptoms [1,6]. The major medications in
asthma management include bronchodilator β2-agonists,
anti-inflammation inhaled corticosteroids, leukotrienetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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agonists in long period may lead to relative refractori-
ness to β2-agonists [7]. Long-acting inhaled β2-agonists,
including formoterol and salmeterol, should never be
used as monotherapy for asthma as these medications
do not appear to influence the airway inflammation in
asthma. They are most effective when combined with in-
haled glucocorticosteroids, and this combination therapy
is the preferred treatment when a medium dose of in-
haled glucocorticosteroid alone fails to achieve control
of asthma [8,9]. Inhaled glucocorticosteroids are cur-
rently the most effective anti-inflammatory medications
for the treatment of persistent asthma. The systemic
side-effects of long-term treatment with high doses of
inhaled glucocorticosteroids include easy bruising, ad-
renal suppression and decreased bone mineral density
and etc. When the drugs are discontinued, deterioration
comes out within weeks to months in proportion of
cases [1]. Leukotriene modifiers are associated with dose
reductions of inhaled glucocorticosteroids, while moni-
toring of liver tests is recommended during their treat-
ment for the underlying liver toxicity [10]. Theophylline,
a bronchodilator, when given in a lower dose, has mod-
est anti-inflammatory properties, but needs proper mon-
itoring for its narrow therapeutic range [11]. As men
tioned above, there is a consistent need to explore novel
effective anti-inflammation and bronchodilator drugs,
especially suitable for the senior and children or chronic
patients.
QFXY is originated from a famous Traditional Chinese
Medicine (TCM) formula “Maxing Shigan Decoction”. It
has been experimentally improved, consisting of eight
materia medicas, Ephedra Herba, Saigae Tataricae Cornu,
Pheretima, Arctii.
Fructus, Lepidii Semen, Bovis Calculus Artifactus, Arme
niacae Semen Amarum and Gypsum Fibrosum. Since de-
cades of extensive clinical practice, QFXY has shown sig-
nificantly therapeutic effects on dissolving phlegm as well
as relieving cough, asthma, upper respiratory tract infec-
tion, bronchitis, pneumonia, and etc., but its underlying
action mechanism still remains elusive [12].
Our previous study revealed QFXY composition with
UPLC/Q-TOF-MS, consisting of 55 ingredients including
27 absorbable constituents [13]. In this study His&Ach-
induced asthma model in guinea pigs was established, and
QFXY was administered orally. HE stained sections were
applied for QFXY effect evaluation. Customized micro-
arrays and 2D electrophoresis (2DE) were adopted to de-
tect differentially expressed genes and proteins (“diff
genes” or “diff proteins” for short) respectively. Some diff
proteins were identified with MALDI-TOF/MS. Cluster,
GO and KEGG analyses enrich the functions and pathways
of the diff genes and proteins. Based on asthma related
genes from GAD and HPRD databases, the interactionnetwork of all diff genes (including both diff genes from
microarrays and diff genes blasted from diff proteins from
2DE) with asthma related genes was achieved, which indi-
cated QFXY had multi-target regulation on asthma. Some
detailed ingredients of QFXY may become candidate anti-
asthma drugs in the future.
Methods
Drugs and animals
QFXY pills (Lot. 100512) were provided by Tianjin
Zhongxin Pharmaceutical Group. Guinea pigs of
England specie, (300 ± 20) g, male and female, were
purchased from Beijing Vital River Laboratory Animal
Technology Co., Ltd. The animals were housed at 22 ±
2°C with 55 ± 10% humidity, 12 h light/dark cycle, and
had free access to species-specific food and tap water.
All experiments were carried out according to the Guide
for the Care and Use of Experimental Animals. Studies
were approved by the Institute Committee of the Animal
Care of Nankai University, China.
Protocol of asthma model
Inside a container, guinea pigs were given the mixed solu-
tion of 0.1% histamine phosphate and 2% acetylcholine
chloride for 10 s with ultrasonic sprayer (0.5 mL/min).
The time when asthma occurred was recorded [14]. The
asthmatic guinea pigs were randomized into 3 groups,
QFXY2 (397.5 mg/100g BW), QFXY1 (or “Q” for short)
(132.5 mg/100g BW) and Model group (“M” for short)
(n=6 for each group), were administrated orally with
QFXY and normal saline respectively for 7 days. Again,
guinea pigs were put into the glass cup and given 0.1% his-
tamine phosphate for 10s, and prolonged period of asthma
was recorded. There was another group without any treat-
ment as the Normal group (“N” for short) for the follow-
ing pathological sections and microarrays. The lung
tissues of guinea pigs prepared for further experiments.
Pathological analysis
HE sections of bronchial and lung tissue of guinea pig
were conducted according to the regular methods [15].
Briefly, the fresh lung tissue samples were fixed in 10%
formalin, and embedded in paraffin. Samples were cross-
cut into 40-50 slices and the thickness of 4-5μm. The
slices were stained by Hematoxylin-Eosin (HE). Finally,
the stained sections were observed in light microscope
(100× and 40×).
Microarray procedures and data analysis
Total RNA of 50mg lung tissues of each group was extracted
[16] with Trizol (Invitrogen, USA), chloroform, isopropanol,
75% ethanol, and purified using Nucleo Spin RNA Clean-up
Kit (MN, Germany). RNA concentration and integrity were
determined by UV-1800 Spectrophotometer (Shimadzu,
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pigs gene expression chips were customized (Agilent
Technologies, USA). The dual-channel chips were
scanned with LuxScan 10KA dual channel laser scanner
(CapitalBio, China). In the primary hybridization pro-
files, cy5 in red, cy3 in green, three chips were QFXY/
Normal, one chip was Model/Normal. The relative dif-
ferential ratio of signal strength, (QFXY/Normal)/
(Model/Normal) presented the relatively varied gene ex-
pression of QFXY/Model. The relative ratios were for
the following SAM (Significance Analysis of Micro-
arrays) analysis for diff gene screening. 2_3, 2_4 and 2_9
were of the QFXY group. RNA of the QFXY group was
isolated from each sample individually and was not
pooled. But RNA samples from the Model group and
Normal group were pooled to reduce biological differ-
ences [17]. SAM One Class method was adopted for the
analysis of diff genes. Standard criteria for diff genes
were |Score (d)| ≥2 and Fold Change≥2 (or ≤0.5). Clus-
ter 3.0 was used with the hierarchical average linkage al-
gorithm to get a heat map. In PubMed, the reference
sequences of guinea pig were blasted to human genes,
with the E value less than 1e-5, and the similarity between
two sequences spanned over half sequence length [18].Figure 1 The pathological sections of each group (HE×40 and HE×10
and E showed lung tissues of guinea pigs around bronchus; B, D and F dis
and QFXY group, obvious inflammatory cell infiltration in mucosa and subm
spongiform vacuoles degeneration, necrosis; Arrow c2 displayed edema of
c3 displayed narrowed or even blocked bronchial lumen, mucous plugs, neThe human genes were imported Molecule Annotation
System (MAS3.0) [19] for GO and Pathway analysis.
2D-electrophoresis and MS identification
Proteins were isolated from 20 mg lung tissues of each
group with RIPA (Radio-Immunoprecipitation Assay) Lysis
Buffer (SolarBio, China) containing 1Mm PMSF (Phenyl-
methanesulfonyl fluoride) for 15min lysis on ice and
centrifuged in 10000g. Protein concentration was diluted to
2mg/ml by Bradford method [20]. In 2D-electrophoresis in-
strument (BIO-RAD), pH 3-l0 precast IEF strips, 0.7 mg
sample loading, total v • h 80000, 120 g/L gel for SDS-
PAGE, and Coomassie brilliant blue staining method was
adopted. The GS-800 scanner was used for acquiring
image, with PDQuest 7.1 software for dot cutting, editing,
detecting and matching. MS analysis providing purity, mo-
lecular weight, amino acid sequence, composition of pep-
tide fragments, as well as the database support, differential
proteins can be identified. Based on the MS report, protein
score greater than 60 or single peptide score over 30 is
more reliable. If more than one protein scored over 60, the
top ranked is more credible. C.I. % over 95% is also reliable
criterion. Besides, we also compared the theoretical protein
molecular weight and isoelectric point with those we0). (A&B) Normal group, (C&D) Model group, (E&F) QFXY group. A, C
played around pulmonary alveoli. Comparing with the Normal group
ucosa seen in Model group. Arrow c1 displayed submucosa of
tracheal mucosa, thickened bronchial walls, more goblet cells; Arrow
crosis mucosa; Arrow d1 displayed alveolar tissue consolidation.
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can be blasted into genes for further study.
Quantitative real-time PCR and data analysis
Validation of changes of diff genes in guinea pig lung tis-
sues was carried out by real-time quantitative polymerase
chain reaction (qPCR). First, total RNA was converted to
cDNA using High Capacity cDNA Reverse Transcription
Kits (ABI, USA). According to the reference sequences of
guinea pig, the primers used are as follows: RHO (forward:
5’-CACCGCTCAACTACATCCTGC-3’, Reverse: 5’- GCC
CGAAGACGAAGTATCCA-3’), GNB1 (forward: 5’- TC
CATCTACAATCTGAAGACTCGC -3’, Reverse: 5’- TAGT
CTGGTGTCGGGAGCG -3’), MAPK3 (forward: 5’- CTC
AACCACATTCTGGGTATCC -3’, Reverse: 5’- CCACCT
TAGTCTTAGAGGGCAGA -3’), CLU (forward: 5’- GGA
TGAAGGACCAGTGCGAG -3’, Reverse: 5’- CGTGGAG
ACATGGAGATAGGC -3’), ENO1 (forward: 5’- CAGAA
GTCACAGCCAGCGTG -3’, Reverse: 5’- CTTTGAGCAG
CAGGCAGTTG -3’), HSP90α (forward: 5’- GGCAGAG
GCTGATAAGAACG -3’, Reverse: 5’- AGTCATCCCTCA
GCCAGAGA -3’), SERPINE2 (forward: 5’- CAGGGTCA
GAAAACCTCCAT -3’, Reverse: 5’- CTGCCCCATGAATAFigure 2 Heat map of the microarrays by hierarchical
clustering. Heat map is a visual diagram, in which the vertical
ordinates showed various chips, and the horizontal ordinates
showed genes expressed in all chips. 2_3, 2_4, 2_9 were of the
QFXY group. N was the Normal group. Red indicated a minimum
two fold increase in expression; green represented a minimum two
fold decrease in expression, compared between the Normal control
and QFXY treatments.ACACAG -3’), GAPDH (forward: 5’- GAACATCATCC
CCGCATCC -3’, Reverse: 5’- GTCCTCGGTGTAGCCCA
AGA -3’). Real-time PCR for quantitative assessment of
mRNA expression was performed on LightCycler 2.0
(Roche, Swiss) with GoTaq qPCR Master Mix (Promega,
USA) according to the manufacturer’s protocol. The PCR
conditions were as follows: 94°C for 2 min, followed by 40
cycles of amplification (95°C for 15 s, 55°C for 30 s, 72°C
for 30 s), and a dissociation stage. 2-ΔΔCt method was ap-
plied for data analysis.
Western blot of Hsp90
The protein sample (40 μg) was separated by 12% denatur-
ing SDS-PAGE and blotted onto a nitrocellulose mem-
brane. After electrophoresis, the proteins were transferred
to nitrocellulose membrane by electrophoretic transfer
system. The membranes were blocked in 5% skimmed
milk in TBS for 1h, and then incubated with primary anti-
body (anti-Hsp90 at 1:2000 dilution and anti-β-actin anti-
bodies at 1:10000 dilution) (Wuhan Boster, China)
overnight at 4°C. The membranes were incubated for
2 h in horseradish peroxidase-conjugated goat anti-rabbit
secondary antibody (1:2500 dilution) for 2 h. Antigen-
antibody complex was visualized by enhanced chemilu-
minescence reagents Supersignal (Pierce, Rockford, IL).
For quantification, Quantity One software (Bio Rad, USA)
was used.
QFXY-asthma target network construction
Human protein interaction data were sourced from Hu-
man Protein Reference Database (HPRD) [21] as the back-
ground. Asthma related genes from Genetic Association
Database (GAD) [22] were annotated to the background
network. Those nodes having direct interactions with
asthma genes were used to build an asthma disease sub-
network. Keep the possibly same interactions in the sub-
network and HPRD network overlapped. By Cytoscape
(Ver. 2.6.0) [23], the diff genes (from both microarray and
2DE data) were annotated in the asthma disease subnet-
work and achieved QFXY-asthma target network.
Statistics
Data were presented as Mean±SD. The significance in
mean values was analyzed by t test for 2 groups and by
analysis of variance (ANOVA) with least squares differ-
ence post-hoc test for more than 2 groups. Values were
considered statistically different at p<0.05.
Results
Histopathological results
To test the QFXY effect, the pathological sections of lung
tissues were stained by HE demonstrated in Figure 1. In
the Model group (Figure 1C and Figure 1D), pathological
sections showed significant edema of tracheal mucosa,
Figure 3 qPCR confirmation of the diff gene expressions with GAPDH as internal reference. Results were expressed as Mean±SD, *p < 0.05,
**p < 0.01 vs. Control group; #p < 0.05, ##p < 0.01 vs. Model group.
Figure 4 The 2DE results of QFXY and Model group. Identified diff proteins were marked by arrows in 2DE of QFXY group and Model group.
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P1 946 100 55703.9 10498.7 5.31 heat shock protein Hsp90-alpha isoform 2
P2 164 100 (−) 2331.6 macrophage-capping protein
P3 151 100 15264.5 25045.8 0.61 microfibrillar-associated protein 4
P4 278 100 (−) 3976.3 gamma-actin
P5 348 100 40773.4 20867.1 1.95 lamin-B1
P6 347 100 16005.9 2196.3 7.29 serine proteinase inhibitor A3K
Zhao et al. BMC Complementary and Alternative Medicine 2013, 13:206 Page 6 of 10
http://www.biomedcentral.com/1472-6882/13/206presenting mucosa epithelial cells swelling, some epithelial
cells in spongiform vacuoles degeneration, necrosis and
loss, and more goblet cells. Narrowed or even blocked
bronchial lumen, thickened smooth muscles of the bron-
chial walls, and mucous plugs were visible and bronchial
vascular congestion and angiogenesis, and inflammatory
cell infiltration in mucosa and submucosa as well as peri-
vascular tissues. In the Normal group (Figure 1A and
Figure 1B), neither was obvious edema in airway mucosa,
nor inflammatory cell infiltration in airway and vascular
vessels. Bronchial tube cavity is smooth and unblocked.
Comparing with the Model group, the QFXY group
(Figure 1E and Figure 1F) has obvious change in bronchialFigure 5 qPCR and Western blot conformation of Hsp90 and
Serpin with QFXY treatment. qPCR validation with GAPDH as
internal reference (A, B). Western blot validation with β-actin as
internal reference (C). Results are expressed as the Mean±SD,
*p < 0.05, **p < 0.01 vs. Control group; #p < 0.05, ##p < 0.01 vs.
Model group. (QF2-397.5mg/100g BW, QF1-132.5mg/100g BW).lung structure, more similar to the Normal group, which
preliminarily showed sound effect.
Microarray analysis and qPCR validation
In our study, guinea pig cDNA microarrays were custom-
ized using the sequences as many as we could archive in
NCBI EST database [24] (19911EST and 930CDS), which
assemble can be used as a microarray design template for
guinea pig. SAM analysis screened 55 diff genes of guinea
pig, with 14 up-regulated and 41 down-regulated, see
Additional file 1. Hierarchical Cluster analysis generated a
heat map, shown in Figure 2, generally revealing gene ex-
pression module comparison of the samples. As shown in
the Heat Map of the Figure 2, 2_4 and 2_9, the expression
profile of the QFXY group had more similarity to that of
the Normal group, which suggested that with the QFXY
treatment, the overall gene expression profiles were in-
clined to the normal level, indicating the mitigation and
improvement of asthma. The gene expression was verified
with qPCR, seen in Figure 3A-3E. The correlation of ex-
pression level in microarray and qPCR seen in Figure 3F.
2DE, MS identification and validation
2DE results were seen in Figure 4. Some diff proteins
were identified using MALDI-TOF/MS seen in Table 1.
Due to limited research data of guinea pig, diff proteins
were blasted into human proteins as well as relevant
genes. Protein expression was validated with qPCR and
Western blot displayed in Figure 5. The expression level
of Hsp90 decreased and Serpin increased with QFXY
treatment comparing with the Model group.
GO and pathway enrichments
There are few guinea pig research data of definite func-
tions of genes and signal pathways. In NCBI, we blasted
55 diff genes of guinea pig and got 27 human homologues,
see Additional file 2. The molecular function, biological
process and cellular component of the 27 diff genes see
Additional file 3, especially involved in such biological
processes as signal transduction, protein phosphorylation,
stress response and etc. The diff genes participate in some
pathways, see Additional file 4. Sourced from KEGG
Figure 6 QFXY-asthma target network based on interactions between all diff genes and asthma related genes. Red for known asthma
genes (resourced from HRPD&GAD), green for diff genes (including those blasted from diff proteins), yellow for diff genes which had direct
interactions with asthma genes, blue for other genes directly interacting with asthma genes.
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ticipated in several common signal pathways, some
of which were involved in inflammation (Hs_TNF-
alpha-NF-κB_NetPath_9, Prostate cancer pathway),
cell movement and proliferation as well as airway
remodelling of the cytoskeleton and extracellular
matrix (Hs_Regulation_of_Actin_Cytoskeleton, extra-
cellular matrix, intermediate filament cytoskeleton,
structural constituent of cytoskeleton, actin binding,
actin cytoskeleton), multi-level signaling protein fold-
ing (protein folding, unfolded protein binding), cell ad-
hesion and signal transduction (Adherens junction, Focal
adhesion), and so on. Important genes involved include
HSP90A1, SERPINA1, MAPK3, ACTG1, VIM, TNNT2,
GNB1, CRYAA, CRYAB, COL4A2, COL1A2 and so on. The
compiled file and detailed pathways see Additional file 5.QFXY-asthma target network
A network containing 1214 nods and 1886 interactions
was constructed as QFXY-asthma target network. In
Figure 6, red for known asthma genes (sourced from
HRPD&GAD), green for diff genes (including those
blasted from diff proteins), yellow for diff genes which
had direct interactions with asthma genes, blue for other
genes directly interacting with asthma genes. In total,
the network contained 16 diff genes, 182 asthma genes
(from databases), and 1016 genes directly interacting
with asthma genes.
Discussion
Studies in animal models form the basis for our current
understanding of the pathophysiology of asthma, and are
central to the preclinical development of drug therapies
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small animal species in preclinical studies related to
asthma and COPD [29]. β2-adenoceptor agonists and
antimuscarinic drugs prevent antigen-induced broncho-
constriction in actively sensitized guinea pigs in a dose-
dependent manner. Histamine is the major mediator in
guinea pigs but not in humans [30]. Asthma is a complex
disease defined by reversible airway narrowing, acute and
chronic airway inflammation, airway hyperresponsiveness
(AHR) and airway tissue remodelling, in which accumula-
tion of airway smooth muscle (ASM) is a prominent and
widely reported feature [31]. In the pharmacodynamics
study, the prolonged asthma time [12] and HE sections
showed that QFXY had significant effects on asthma, re-
ducing edema in airway mucosa and inflammatory cell in-
filtration in airway and vascular vessels. They were also
beneficial to reducing airway remodelling.
Among up-regulated genes, the fold change of RHO
almost ranked top (Additional file 2). Among down-
regulated genes, CLU and ENO1 had greater changes.
Among 2D results, fold changes of Hsp90 and Serpin
were of greater change (Table 1). Besides, references
and literatures about every diff molecules were re-
trieved, of which some were related to the process of
inflammation or asthma or lung diseases, such as
GNB1 [32,33], MAPK3 [34-37]. Altogether, with the
combined consideration of fold changes and refer-
ences, these genes (RHO, CLU, ENO1, GNB1, MAPK3)
and proteins (Hsp90, Serpin) were selected for vali-
dation test.
The GO annotation suggested that QFXY might influ-
ence the inflammation, signal transduction, stress re-
sponse, the apoptosis of endothelial and bronchial cells.
Pathway analysis revealed that different genes were in-
volved in the signaling pathways, including focal ad-
hesion pathway, cell-extracellular matrix interactions
pathway, TGF-beta signaling pathways, NK cell-me
diated cytotoxic pathway and so on, which are all related
with cell signaling, inflammation, mast cells and NK
cells. Many asthma drugs also participated in those path-
ways in variety of mechanisms, targeting kinases, recep-
tors or related proteins, affecting inflammation response,
mitosis, angiogenesis, apoptosis, and anti-oxidation, to
play a role in asthma. The qPCR change profile was ba-
sically in line with the microarray results, proving the re-
liability of microarray data. The commonly shared signal
pathways of diff genes and diff proteins combined the
genomics and proteomics together, to manifest the
underlying mechanism of QFXY effects.
The Mapk3/Erk signaling cascade is a central Mapk
pathway that plays a role in the regulation of various
cellular processes such as proliferation, differentiation,
development, and inflammation reactions and etc.
[34-37]. Inhibition of this kinase strongly decreased theexpression of pro-inflammatory genes encoding growth-
regulated proteins (Gro-a, Gro-b and Gro-g) and inter-
leukins (IL-1β, IL-6 and IL-8) [36]. Mapk can participate
in the regulation of NF-κB transcriptional activity
[38,39]. Our previous study also presented decreasing
erk expression and NF-κB inhibition [13].
Hsp90, as a molecular chaperone, has interactions with
proteins, such as Akt and Raf-1 [40]. Akt is a down-
stream effecter molecule of phosphoinositide 3-kinase
and is thought to mediate many immune and inflamma-
tory responses. It is also involved in the activation of
NF-κB [41]. Amino acid residues 229–309 of Akt were
involved in the binding to Hsp90 and amino acid resi-
dues 327–340 of Hsp90 β were involved in the binding
to Akt [42]. Hsp90 plays an important role in main-
taining Akt kinase activity. In our study, 2D and West-
ern blot showed decreased Hsp90 after QFXY treatment,
as well as less NF-κB activity [13], indicating QFXY may
affect the binding of Hsp90 and Akt, which needs fur-
ther confirmation.
GTP-binding protein beta1 subunit gene (GNB1), its
up-regulation appears to be one of the candidate pro-
cesses of sensitization. It also has NF-κB recognition
sites [32]. The Ectodysplasin is involved in binding to its
ligand EDA-A1 and activates the NF-κB intracellular
signaling pathway by interaction through its death
domain with the adaptor protein EDARADD [33].
Down-regulated GNB1 and EDARADD gene expression
decreased NF-κB activity for anti-inflammation.
Serpins form an enormous superfamily of 40-60-kDa
proteins found in almost all types of organisms. Most
have evolved to finely regulate complex proteolytic
pathways, such as blood coagulation, fibrinolysis, and in-
flammation [43,44]. α1-antitrypsin (AAT) is an archetype
member of the serpin supergene family. The reduced
serum levels of AAT contribute to the development of
chronic obstructive pulmonary disease (COPD).
In addition to protease inhibition, AAT shows anti-in
flammatory, immunomodulatory and antimicrobial pro-
perties [45,46]. SerpinA1 is an endogenous anti-
inflammatory factor, and its anti-inflammatory effects
may be mediated through antioxidant activity [47]. Com-
pared with the Model group, the HE sections of the
QFXY group showed less inflammation and mucosa
hyperplasia, and the 2D and qPCR proved higher
SerpinA1 expression, which indicating specific ingredi-
ents in QFXY can activate SerpinA1.
Asthma is a disease characterized by persistent inflam-
mation and structural changes in the airways referred to
as airway remodelling., including smooth muscle hyper-
trophy, goblet cell hyperplasia, subepithelial fibrosis, and
angiogenesis. Vascular remodelling in asthmatic lungs
results from increased angiogenesis, mediated by vas-
cular endothelial growth factor (VEGF). In addition,
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sensitization, and has a role in Th2 type inflammatory
responses [48]. Matrix GLA protein (MGP) has a role in
endothelial cell (EC) function [49]. MGP modulates the
activity of transforming growth factor (TGF)-β super-
family, which is critical for morphogenesis and develop-
ment [50]. MGP can stimulate VEGF expression through
increased TGF-β activity in endothelial cells [51]. Com-
paring with the Model group, HE sections in the QFXY
group showed less pulmonary consolidation, which
means QFXY help alleviate lung tissue remodelling.
Asthma is featured by reversible airway obstruction.
The lack of full reversibility in some asthmatic patients
may be due to chronic airway remodelling [52]. It ap-
pears that inflammation and remodelling are inter-
dependent processes that clearly influence the clinical
long term evolution of asthma [53]. The ECM can act as
a reservoir for an increasing number of growth factors.
These growth factors can be rapidly released from the
ECM to allow extracellular signaling regulated by the
growth factors to proceed without the need for new pro-
tein synthesis [54].
In QFXY-asthma target network, Hsp90α, Mapk3,
VIM were hub proteins suggesting that they may be
some targets of QFXY pills. The complicated interaction
network suggested that QFXY pills affected a complex
system regulating inflammation and immune reactions.
Seen from the above complex network, QFXY interacts
with asthma related genes in both direct and indirect
way, affecting several signal pathways. In the previous
study, 55 ingredients have been identified, including 27
absorbable constituents in QFXY, among which there
are 19 ingredients affect inflammatory pathways, typic-
ally they are sulfur containing alkynes, such as arctic
acid; lignans, such as arctigenin; phenolic acids, such as
sinapic acid; steroids, such as cholic acid [13]. In the fol-
lowing study, other effects of these ingredients, such as
alleviating airway hyperresponsiveness (AHR) and airway
tissue remodelling will be further explored.
Conclusions
A primarily combined genomic and proteomic screen
of QFXY targets displayed a series of candidate genes
and proteins, which indicated that the effect of QFXY
relied on combined mechanism, anti-inflammation and
anti-remodelling, as well as influence signal transduc-
tion in vivo.
Additional files
Additional file 1: List of diff genes of microarrays.xls
Additional file 2: Blasting list of diff genes.xls
Additional file 3: GO analysis of diff genes.xlsAdditional file 4: KEGG pathways analysis of diff genes.xls
Additional file 5: List of commonly shared pathway (sourced from
KEGG, GenMAPP, and BioCarta) by diff genes and diff proteins.doc
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
ZZ, GB and HW contributed to the conception and design of the study.
ZZ completed the experiment. YM assisted the bioinformatics, PP finished
2D-MS, BC assisted the animal models. ZZ and HW drafted the manuscript.
All authors contributed to further writing of the manuscript. All authors read
and approved of the final manuscript.
Acknowledgements
This study was financially supported by grants from the National Nature
Science Fund (NNSF) of China (No. 81173638). Thanks to Professor Gu’an
Luo, Associate Professor Yuanyuan Hou and Lecturer Min Jiang and
Chunfeng Xie, for their sincere instructions and help. Also thanks to Professor
Xiaobo Tang and researcher Chuanfei Yu and Shan Yun for their advice on
English writing.
Author details
1College of Pharmacy, Nankai University, Tianjin, People's Republic of China.
2Department of Pharmacy, Tianjin People’s Hospital, Tianjin, People's
Republic of China. 3Department of Pharmacology, Tianjin Medical University,
Tianjin, People's Republic of China.
Received: 25 March 2013 Accepted: 2 August 2013
Published: 6 August 2013
References
1. Bateman ED, Hurd SS, Barnes PJ, Bousquet J, Drazen JM, FitzGerald M,
Gibson P, Ohta K, O'Byrne P, Pedersen SE, Pizzichini E, Sullivan SD, Wenzel
SE, Zar HJ: Global strategy for asthma management and prevention:
GINA executive summary. Eur Respir J 2008, 31(1):143–178.
2. Holgate ST, Davies DE: Rethinking the pathogenesis of asthma. Immunity
2009, 31(3):362–367.
3. Gern JE, Lemanske RF, Busse WW: Early life origins of asthma. J Clin Invest
1999, 104(7):837–843.
4. Claudio L, Tulton L, Doucette J, Landrigan PJ: Socioeconomic factors and
asthma hospitalization rates in New York City. J Asthma 1999,
36(4):327–343.
5. Bousquet J, Jeffery PK, Busse WW, Johnson M, Vignola AM: Asthma From
bronchoconstriction to airways inflammation and remodeling. Am J
Respir Crit Care Med 2000, 161(5):1720–1745.
6. Kroegel C: Global Initiative for Asthma (GINA) guidelines: 15 years of
application. Expert Rev Clin Immunol 2009, 5(3):239–249.
7. Dorinsky: The salmeterol multicenter asthma research trial: A comparison
of usual pharmacotherapy for asthma or usual pharmacotherapy plus
salmeterol (vol 129, pg 15, 2006). Chest 2006, 129(5):1393.
8. Gibson PG, Powell H, Ducharme FM: Differential effects of maintenance
long-acting beta-agonist and inhaled corticosteroid on asthma control
and asthma exacerbations. J Allergy Clin Immun 2007, 119(2):344–350.
9. Lemanske RF, Sorkness CA, Mauger EA, Lazarus SC, Boushey HA, Fahy JV,
Drazen JM, Chinchilli VM, Craig T, Fish JE, Ford JG, Israel E, Kraft M, Martin RJ,
Nachman SA, Peters SP, Spahn JD, Szefler SJ: Inhaled corticosteroid
reduction and elimination in patients with persistent asthma receiving
salmeterol - A randomized controlled trial. Jama-J Am Med Assoc 2001,
285(20):2594–2603.
10. Wechsler ME, Pauwels R, Drazen JM: Leukotriene modifiers and Churg-
Strauss syndrome - Adverse effect or response to corticosteroid
withdrawal? Drug Saf 1999, 21(4):241–251.
11. Barnes PJ: Theophylline - New perspectives for an old drug. Am J Resp
Crit Care 2003, 167(6):813–818.
12. Hou Y, Li R, Shi Q, Cheng B, Wang L, Bai R: Investigation of the Anti-
asthmatic Mechanism of QingFeiXiaoYanWan. Acta Scientiarum
Naturalium Universitatis Nankaiensis 2009, 5:103–107.
13. Cheng B, Hou Y, Wang L, Dong L, Peng J, Bai G: Dual-bioactivity-based
liquid chromatography-coupled quadrupole time-of-flight mass
Zhao et al. BMC Complementary and Alternative Medicine 2013, 13:206 Page 10 of 10
http://www.biomedcentral.com/1472-6882/13/206spectrometry for NF-kappaB inhibitors and beta2AR agonists
identification in Chinese Medicinal Preparation Qingfei Xiaoyan Wan.
Anal Bioanal Chem 2012, 404(8):2445–2452.
14. Vogel G, Vogel WH, Vogel HG: Drug Discovery and Evaluation:
Pharmacological Assays. Berlin: Springer; 1997.
15. Fan X, Shi M, Wang Y, Liang Q, Luo G: Transcriptional profiling analysis of
HMP-treated rats with experimentally induced myocardial infarction.
J Ethnopharmacol 2011, 137(1):199–204.
16. Mutter GL, Zahrieh D, Liu CM, Neuberg D, Finkelstein D, Baker HE,
Warrington JA: Comparison of frozen and RNALater solid tissue storage
methods for use in RNA expression microarrays. BMC Genomics 2004,
5:88–94.
17. Pedotti P, Hoen PA T, Vreugdenhil E, Schenk GJ, Vossen RH, Ariyurek Y,
De Hollander M, Kuiper R, Van Ommen G, Den Dunnen JT, Boer JM, De
Menezes RX: Can subtle changes in gene expression be consistently
detected with different microarray platforms? BMC Genomics 2008, 9:124–136.
18. Basic BLAST. http://blast.ncbi.nlm.nih.gov/Blast.cgi.
19. Molecule Annotation System. http://bioinfo.capitalbio.com/mas3/.
20. Fan X, Li X, Lv S, Wang Y, Zhao Y, Luo G: Comparative proteomics
research on rat MSCs differentiation induced by Shuanglong Formula.
J Ethnopharmacol 2010, 131(3):575–580.
21. Human Protein Reference Database. http://www.hprd.org/.
22. Genetic Association Database. http://geneticassociationdb.nih.gov/.
23. Cline MS, Smoot M, Cerami E, Kuchinsky A, Landys N, Workman C, Christmas
R, Avila-Campilo I, Creech M, Gross B, Hanspers K, Isserlin R, Kelley R,
Killcoyne S, Lotia S, Maere S, Morris J, Ono K, Pavlovic V, Pico AR, Vailaya A,
Wang PL, Adler A, Conklin BR, Hood L, Kuiper M, Sander C, Schmulevich I,
Schwikowski B, Warner GJ, et al: Integration of biological networks and
gene expression data using Cytoscape. Nat Protoc 2007, 2(10):2366–2382.
24. NCBI EST database. http://www.ncbi.nlm.nih.gov/nucest/.
25. KEGG PATHWAY Database. http://www.genome.jp/kegg/pathway.html.
26. GenMapp: Gene Map Annotation and Pathway Profiler. http://www.genmapp.
org/default.html.
27. BioCarta. http://www.biocarta.com/genes/index.asp.
28. Bates JH, Rincon M, Irvin CG: Animal models of asthma. Am J Physiol Lung
Cell Mol Physiol 2009, 297(3):L401–L410.
29. Canning BJ: Modeling asthma and COPD in animals: a pointless exercise?
Curr Opin Pharmacol 2003, 3(3):244–250.
30. Szelenyi I: Animal models of bronchial asthma. Inflamm Res 2000,
49(12):639–654.
31. Holgate ST: Pathogenesis of asthma. Clin Exp Allergy 2008, 38(6):872–897.
32. Kitanaka J, Kitanaka N, Takemura M, Wang XB, Hembree CM, Goodman NL,
Uhl GR: Isolation and Sequencing of a putative promoter region of the
murine G protein beta 1 subunit (GNB1) gene. Dna Sequence 2002,
13(1):39–45.
33. Moya-Quiles MR, Ballesta-Martinez MJ, Lopez-Gonzalez V, Glover G,
Guillen-Navarro E: A compound heterozygous mutation in the EDAR gene
in a Spanish family with autosomal recessive hypohidrotic ectodermal
dysplasia. Arch Dermatol Res 2010, 302(4):307–310.
34. Shaul YD, Seger R: The MEK/ERK cascade: From signaling specificity to
diverse functions. Bba-Mol Cell Res 2007, 1773(8):1213–1226.
35. McCubrey JA, Milella M, Tafuri A, Martelli AM, Lunghi P, Bonati A, Cervello
M, Lee JT, Steelman LS: Targeting the Raf/MEK/ERK pathway with small-
molecule inhibitors. Curr Opin Investig Drugs 2008, 9(6):614–630.
36. Verhaeghe C, Remouchamps C, Hennuy B, Vanderplasschen A, Chariot A,
Tabruyn SP, Oury C, Bours V: Role of IKK and ERK pathways in intrinsic
inflammation of cystic fibrosis airways. Biochem Pharmacol 2007,
73(12):1982–1994.
37. Perkins ND: Post-translational modifications regulating the activity and
function of the nuclear factor kappa B pathway. Oncogene 2006,
25(51):6717–6730.
38. Weiss T, Shalit I, Blau H, Werber S, Halperin D, Levitov A, Fabian I:
Anti-inflammatory effects of moxifloxacin on activated human
monocytic cells: Inhibition of NF-KB and mitogen-activated protein
kinase activation and of synthesis of proinflammatory ctokines.
Antimicrob Agents Ch 2004, 48(6):1974–1982.
39. Lee FS, Peters RT, Dang LC, Maniatis T: MEKK1 activates both I kappa B
kinase alpha and I kappa B kinase beta. P Natl Acad Sci Usa 1998,
95(16):9319–9324.
40. Fontana J, Fulton D, Chen Y, Fairchild TA, McCabe TJ, Fujita N, Tsuruo T,
Sessa WC: Domain mapping studies reveal that the M domain of hsp90serves as a molecular scaffold to regulate Akt-dependent
phosphorylation of endothelial nitric oxide synthase and NO release.
Circ Res 2002, 90(8):866–873.
41. Ozes ON, Mayo LD, Gustin JA, Pfeffer SR, Pfeffer LM, Donner DB: NF-kappa
B activation by tumour necrosis factor requires the Akt serine-threonine
kinase. Nature 1999, 401(6748):82–85.
42. Sato S, Fujita N, Tsuruo T: Modulation of Akt kinase activity by binding to
Hsp90. P Natl Acad Sci Usa 2000, 97(20):10832–10837.
43. Gettins P, Olson ST: Exosite Determinants of Serpin Specificity. J Biol Chem
2009, 284(31):20441–20445.
44. Ekeowa UI, Marciniak SJ, Lomas DA: alpha(1)-antitrypsin deficiency and
inflammation. Expert Rev Clin Immunol 2011, 7(2):243–252.
45. Janciauskiene SM, Bals R, Koczulla R, Vogelmeier C, Kohnlein T, Welte T:
The discovery of alpha 1-antitrypsin and its rote in health and disease.
Resp Med 2011, 105(8):1129–1139.
46. Shigetomi H, Onogi A, Kajiwara H, Yoshida S, Furukawa N, Haruta S, Tanase
Y, Kanayama S, Noguchi T, Yamada Y, Oi H, Kobayashi H: Anti-inflammatory
actions of serine protease inhibitors containing the Kunitz domain.
Inflamm Res 2010, 59(9):679–687.
47. Zhang B, Hu Y, Ma JX: Anti-inflammatory and antioxidant effects of
SERPINA3K in the retina. Invest Ophthalmol Vis Sci 2009, 50(8):3943–3952.
48. Meyer N, Akdis CA: Vascular Endothelial Growth Factor as a Key Inducer
of Angiogenesis in the Asthmatic Airways. Curr Allergy Asthma Rep 2013,
13(1):1–9.
49. Budd DC, Holmes AM: Targeting TGF beta superfamily ligand accessory
proteins as novel therapeutics for chronic lung disorders.
Pharmacol Therapeut 2012, 135(3):279–291.
50. Engelse MA, Neele JA, Bronckers A, Pannekoek H, De Vries C: Vascular
calcification: expression patterns of the osteoblast-specific gene core
binding factor alpha-1 and the protective factor matrix gla protein in
human atherogenesis. Cardiovasc Res 2001, 52(2):281–289.
51. Bostrom K, Zebboudj AF, Yao YC, Lin TS, Torres A: Matrix GLA protein
stimulates VEGF expression through increased transforming growth
factor-beta 1 activity in endothelial cells. J Biol Chem 2004,
279(51):52904–52913.
52. Boulet LP, Turcotte H, Laviolette M, Naud F, Bernier MC, Martel S, Chakir J:
Airway hyperresponsiveness, inflammation, and subepithelial collagen
deposition in recently diagnosed versus long-standing mild
asthma - Influence of inhaled corticosteroids. Am J Resp Crit Care 2000,
162(4):1308–1313.
53. Vignola AM, Mirabella F, Costanzo G, Di Giorgi R, Gjomarkaj M, Bellia V,
Bonsignore G: Airway remodeling in asthma. Chest 2003,
123S(3):417S–422S.
54. Burgess JK: The role of the extracellular matrix and specific growth
factors in the regulation of inflammation and remodelling in asthma.
Pharmacol Therapeut 2009, 122(1):19–29.
doi:10.1186/1472-6882-13-206
Cite this article as: Zhao et al.: Qingfei Xiaoyan Wan alleviates asthma
through multi-target network regulation. BMC Complementary and
Alternative Medicine 2013 13:206.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
